AMPL Al-madina Pharmaceuticals Limited
Pharmaceuticals & Chemicals
Tk 72.8 as of 2026-11-12 14:01:30
Rank 141 of all scored
Data completeness 60%
Data completeness 60%
Score breakdown
Consistency —
Profitability —
Solvency 93
Valuation 11
Weights: consistency 30%, profitability 30%, solvency 20%, valuation 20%; then risk flags add or subtract points. Full method
Why this score
Strengths
- Solvency Low debt: debt/equity 0.26x (below 0.5)
Concerns
- Valuation P/E 125.52 is high (above 20)
- Valuation Trades at 3.53x book value (NAV Tk 20.61, price Tk 72.8)
- Valuation Price is 344% above the Graham fair value (Tk 16.4)
Risk flags
- Small cap (< Tk 200 cr): most exposed to manipulation and volatility
Valuation
P/E
P/E audited
P/E current
P/B
NAV per share
EPS (last audited year)
Graham fair value
Margin of safety
52-week range
178.9% above the low, 33.8% below the high. Near the low is only interesting if profit is intact (see concerns above) and the fall has a temporary cause.
Quality and growth
ROE
ROE avg
ROE min
Profit CAGR
Profit YoY
Net profit
EPS up
Loss years (last ~5)
Dividends and safety
Div years
Dividend yield
Payout
Cash div
D/E
Loans/MCap
Size, liquidity and ownership
MCap
Free float
Daily turnover
Sponsor %
Inst. %
Public %
Foreign %
Shareholding
- Sponsor/director 55%
- Institution 4.6%
- Public 40.4%
Shariah screen (partial)
Business screen and the debt ratio (loans / market cap 7.4%, limit 33%) are automated. Interest income (under 5% of revenue) and cash/investment ratios must be checked in the annual report.
Educational, not investment advice. Verify on DSE and StockNow before making any decision.